MapLight Therapeutics's net income is $-230M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Loading...
Loading...
MapLight Therapeutics (MPLT) currently reports a net income of $-230M as of June 2026. That compares with $-92M in the prior-year period — down 148.6% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore MapLight Therapeutics's net income history and peer comparisons.
MapLight Therapeutics's net income decreased from $-92M to $-230M — a 148.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
MapLight Therapeutics's net income of $-230M is lower than the Healthcare sector average of $16B. That is roughly 101.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
MapLight Therapeutics reported $-230M in net income as of June 2026. That compares with $-92M in the prior-year period — down 148.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $-230M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for MapLight Therapeutics, and consider following MPLT for alerts when major investors trade the stock.